news-med.jpg

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter

Our recent collaboration with Massachusetts General Hospital (MGH) on the identification and validation of novel targets in Gram-negative bacteria is covered in the Spring edition of OneNucleus Newsletter. Read the full article on page 8 with our expert, Antonio Felici.

Topics: Drug design and discovery, Antibiotic Resistance, Gram-negative bacteria, Partner Research Organization, Antibacterial Read More

Why We Need a Culture of International Collaboration to Fight Antibiotic Resistance

Read the article on antimicrobial resistance from our very own Antonio Felici, which was published in Bioscience Technology this month. Read full article from Bioscience Technology online site

Topics: Drug design and discovery, Antibiotic Resistance, Drug Discovery Read More

Pharma's Almanac on Aptuit's Collaboration with Bioversys

Nice coverage in Pharma's Almanac of Aptuit's collaboration with Bioversys. Aptuit in Bacteria Resistance Collaboration Drug development firm Aptuit has begun a joint collaboration with the Swiss biotech Bioversys that is aimed at the identification and validation of novel targets and molecules for ...

Topics: Drug design and discovery, Antibiotic Resistance Read More

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address ...

Topics: Drug design and discovery, Antibiotic Resistance, Drug Discovery, Gram-negative bacteria, Partner Research Organization Read More